NCT00447577View on ClinicalTrials.gov

Zylet vs TobraDex in Blepharokeratoconjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Blepharokeratoconjunctivitis
Interventions
DRUG

Loteprednol etabonate and tobramycin ophthalmic suspension

Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.

DRUG

Tobramycin and dexamethasone ophthalmic suspension

Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.

Trial Locations (1)

27262

Cornerstone Eye Care, High Point

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT00447577 - Zylet vs TobraDex in Blepharokeratoconjunctivitis | Biotech Hunter | Biotech Hunter